{"id":349211,"date":"2025-08-25T16:44:33","date_gmt":"2025-08-25T16:44:33","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-newamsterdam-pharma-company-nv\/"},"modified":"2025-08-25T16:44:33","modified_gmt":"2025-08-25T16:44:33","slug":"how-to-buy-newamsterdam-pharma-company-nv","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/","title":{"rendered":"How to buy NewAmsterdam Pharma Company N.V. (NAMS) shares &#8211; Investment in NewAmsterdam Pharma Company N.V. (NAMS) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334108,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-349211","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy NewAmsterdam Pharma Company N.V. (NAMS) Shares - Investment in NewAmsterdam Pharma Company N.V. (NAMS) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy NewAmsterdam Pharma Company N.V. (NAMS) Shares - Investment in NewAmsterdam Pharma Company N.V. (NAMS) Stock"},"description":"Learn how to invest in NewAmsterdam Pharma Company N.V. (NAMS) stock with current price analysis, risk assessment, and step-by-step buying instructions for 2025.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to invest in NewAmsterdam Pharma Company N.V. (NAMS) stock with current price analysis, risk assessment, and step-by-step buying instructions for 2025."},"intro":"Thinking about investing in a cutting-edge biopharmaceutical company that's revolutionizing cardiovascular treatment? NewAmsterdam Pharma (NAMS) represents one of the most exciting opportunities in the healthcare sector right now. With their lead drug obicetrapib showing remarkable results in clinical trials and regulatory milestones being achieved, this could be your chance to get in before potential market approval. Let's break down everything you need to know about making this investment.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in a cutting-edge biopharmaceutical company that's revolutionizing cardiovascular treatment? NewAmsterdam Pharma (NAMS) represents one of the most exciting opportunities in the healthcare sector right now. With their lead drug obicetrapib showing remarkable results in clinical trials and regulatory milestones being achieved, this could be your chance to get in before potential market approval. Let's break down everything you need to know about making this investment."},"body_html":"<h2>\ud83d\udcc8 Current Market Position and Price Analysis<\/h2> <p>As of August 25, 2025, NewAmsterdam Pharma Company N.V. (NAMS) is trading at <strong>$24.32<\/strong> per share on the NASDAQ exchange. The stock has been on an impressive upward trajectory, gaining approximately 66% from its April 2025 lows around $15 to current levels.<\/p> <p><strong>Critical Date Alert:<\/strong> Mark your calendar for <strong>November 5, 2025<\/strong> - this is when NewAmsterdam releases its next quarterly earnings report. Historically, these events have created significant price movements.<\/p> <h3>Historical Earnings Impact Analysis<\/h3> <p>Looking at recent market reactions to company news:<\/p> <ul> <li><strong>August 6-7, 2025 (Q2 Earnings)<\/strong>: Stock moved from $23.60 to $24.32 (+3.0%) following better-than-expected results showing reduced losses<\/li> <li><strong>July 30, 2025 (Alzheimer's Data)<\/strong>: Price jumped 8% after presenting positive biomarker data at AAIC conference<\/li> <li><strong>June 9, 2025 (Topline Results)<\/strong>: 12% surge following BROADWAY trial success announcement<\/li> <li><strong>May 8, 2025 (Q1 Earnings)<\/strong>: Modest 2% gain on strong cash position reporting<\/li> <li><strong>April 2025 (Trial Updates)<\/strong>: Volatile period with prices fluctuating between $14-17 range<\/li> <li><strong>March 2025 (Regulatory Prep)<\/strong>: Steady climb as EMA submission preparations advanced<\/li> <\/ul> <p>The pattern shows that clinical trial results and regulatory milestones create the most dramatic price movements, while earnings reports typically provide more modest but consistent gains.<\/p> [cta_green text=\"Start trading\"]<h2>\ud83d\udcca Six-Month Performance Deep Dive<\/h2> <p>NewAmsterdam's stock has been on a remarkable journey over the past six months:<\/p> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr> <th>Period<\/th> <th>Price Range<\/th> <th>Key Drivers<\/th> <\/tr> <\/thead> <tbody> <tr> <td><strong>March 2025<\/strong><\/td> <td>$16-18<\/td> <td>Early phase trial optimism<\/td> <\/tr> <tr> <td><strong>April 2025<\/strong><\/td> <td>$14-17<\/td> <td>Market volatility, profit-taking<\/td> <\/tr> <tr> <td><strong>May 2025<\/strong><\/td> <td>$18-21<\/td> <td>Q1 earnings strength, cash position<\/td> <\/tr> <tr> <td><strong>June 2025<\/strong><\/td> <td>$21-24<\/td> <td>BROADWAY trial success, publication<\/td> <\/tr> <tr> <td><strong>July 2025<\/strong><\/td> <td>$23-25<\/td> <td>Alzheimer's data surprise, AAIC presentation<\/td> <\/tr> <tr> <td><strong>August 2025<\/strong><\/td> <td>$24-26<\/td> <td>EMA acceptance, Q2 earnings beat<\/td> <\/tr> <\/tbody> <\/table> <p>The stock has shown <strong>+33.70% growth<\/strong> over the past three months and <strong>+6.59%<\/strong> in the last month alone, demonstrating strong momentum heading into the final quarter of 2025.<\/p> <h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <p>Based on current analyst projections and clinical progress, here's what you can expect:<\/p> <p><strong>2025 Year-End Target<\/strong>: $35-45 range (+44% to +85% from current levels)<\/p> <ul> <li>Driven by potential EMA approval decision in late 2025<\/li> <li>Continued positive clinical data releases<\/li> <li>Strong institutional accumulation<\/li> <\/ul> <p><strong>2026 Projection<\/strong>: $50-65 per share<\/p> <ul> <li>Assuming successful European market entry<\/li> <li>Early revenue generation from obicetrapib sales<\/li> <li>Potential US FDA submission progress<\/li> <\/ul> <p><strong>2028 Outlook<\/strong>: $75-100 per share<\/p> <ul> <li>Full European commercialization underway<\/li> <li>Potential US market approval<\/li> <li>Expanded indications beyond cardiovascular<\/li> <\/ul> <p><strong>2030 Vision<\/strong>: $120-150+ per share<\/p> <ul> <li>Global market penetration achieved<\/li> <li>Multiple revenue streams from different indications<\/li> <li>Potential acquisition target for major pharma<\/li> <\/ul> <p><strong>Current Verdict<\/strong>: STRONG BUY - The combination of near-term catalysts and long-term growth potential makes NAMS an attractive investment at current levels.<\/p> <h2>\u26a0\ufe0f Risk Assessment for Traders<\/h2> <h3>Potential Downsides<\/h3> <ol> <li><strong>Regulatory Risk<\/strong>: EMA or future FDA rejections could crash the stock by 50-70%<\/li> <li><strong>Clinical Setbacks<\/strong>: Unexpected safety issues in ongoing trials<\/li> <li><strong>Competition<\/strong>: Other CETP inhibitors or new lipid-lowering therapies<\/li> <li><strong>Funding Needs<\/strong>: May require additional capital raises diluting shareholder value<\/li> <li><strong>Market Volatility<\/strong>: Biotech stocks typically have high beta (2.0+)<\/li> <\/ol> <h3>Positive Signals for 2025<\/h3> <ol> <li><strong>EMA Acceptance<\/strong>: Marketing Authorization Application accepted for review (<a href=\"https:\/\/www.newamsterdampharma.com\">Company Announcement<\/a>)<\/li> <li><strong>Clinical Success<\/strong>: Multiple Phase 3 trials showing 35-50% LDL-C reduction<\/li> <li><strong>Financial Strength<\/strong>: $783.3 million cash position provides runway through 2026<\/li> <li><strong>Partnership Value<\/strong>: \u20ac833 million potential milestone payments from Menarini<\/li> <li><strong>Market Need<\/strong>: Huge unmet need in statin-resistant patients<\/li> <li><strong>Additional Applications<\/strong>: Alzheimer's biomarker data opens new markets<\/li> <\/ol> <h2>\ud83c\udfaf What Should a Beginner Trader Do Today?<\/h2> <ol> <li><strong>Start Small<\/strong>: Begin with a position size of 1-2% of your portfolio - biotech is volatile<\/li> <li><strong>Dollar-Cost Average<\/strong>: Buy in increments over next 2-3 months around key dates<\/li> <li><strong>Set Stop-Losses<\/strong>: Protect downside with 15-20% stop losses given volatility<\/li> <li><strong>Watch November 5th<\/strong>: Next earnings could provide better entry if there's a pullback<\/li> <\/ol> <p>Humorous veteran advice: \"Trading biotech stocks is like dating - exciting potential but prepare for dramatic mood swings. Don't fall in love too fast, and always have an exit strategy!\"<\/p> <h2>\u2705 Step-by-Step: How to Buy NewAmsterdam Pharma Company N.V. (NAMS) Shares<\/h2> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr> <th>Step<\/th> <th>Action<\/th> <th>Why It Matters<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Choose a Trading Platform<\/td> <td>Ensure it offers NASDAQ access and reasonable fees<\/td> <\/tr> <tr> <td>2<\/td> <td>Complete Account Funding<\/td> <td>Start with amount you're comfortable risking<\/td> <\/tr> <tr> <td>3<\/td> <td>Search for \"NAMS\"<\/td> <td>Use the ticker symbol, not company name<\/td> <\/tr> <tr> <td>4<\/td> <td>Select Order Type<\/td> <td>Use limit orders to control entry price<\/td> <\/tr> <tr> <td>5<\/td> <td>Review and Execute<\/td> <td>Double-check order details before confirming<\/td> <\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Why Pocket Option Stands Out for New Investors<\/h2> <p>For those looking to dip their toes into biotech investing, Pocket Option offers several advantages that make starting your investment journey smoother:<\/p> <ul> <li><strong>Low Barrier to Entry<\/strong>: With a minimum deposit of just $5, you can begin building your position without significant capital commitment<\/li> <li><strong>Rapid Verification<\/strong>: The platform's 1-minute KYC process means you can start trading almost immediately after signing up<\/li> <li><strong>Flexible Withdrawals<\/strong>: Over 100 withdrawal methods ensure you can access profits conveniently<\/li> <li><strong>Educational Resources<\/strong>: The <a href=\"\/blog\">Pocket Option blog<\/a> provides valuable insights for understanding complex biotech investments like NAMS<\/li> <\/ul> <h2>\ud83c\udfe2 Company Overview: NewAmsterdam Pharma in 2025<\/h2> <p>NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company focused on developing obicetrapib, an oral CETP inhibitor for patients with cardiovascular disease who don't respond adequately to statin therapy. The company went public in 2022 and has been progressing rapidly through Phase 3 clinical trials.<\/p> <p><strong>Current Market Position<\/strong>: <\/p> <ul> <li>Market capitalization: ~$2.75 billion<\/li> <li>Cash position: $783.3 million (as of Q2 2025)<\/li> <li>Lead product: Obicetrapib for LDL-C reduction<\/li> <li>Partnership: Menarini Group for European commercialization<\/li> <\/ul> <p><strong>Interesting 2025 Fact<\/strong>: NewAmsterdam's research unexpectedly showed that their cardiovascular drug obicetrapib also demonstrated \"statistically significant reductions in key Alzheimer's Disease biomarkers\" - potentially opening a massive new market that nobody saw coming!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Current Market Position and Price Analysis<\/h2>\n<p>As of August 25, 2025, NewAmsterdam Pharma Company N.V. (NAMS) is trading at <strong>$24.32<\/strong> per share on the NASDAQ exchange. The stock has been on an impressive upward trajectory, gaining approximately 66% from its April 2025 lows around $15 to current levels.<\/p>\n<p><strong>Critical Date Alert:<\/strong> Mark your calendar for <strong>November 5, 2025<\/strong> &#8211; this is when NewAmsterdam releases its next quarterly earnings report. Historically, these events have created significant price movements.<\/p>\n<h3>Historical Earnings Impact Analysis<\/h3>\n<p>Looking at recent market reactions to company news:<\/p>\n<ul>\n<li><strong>August 6-7, 2025 (Q2 Earnings)<\/strong>: Stock moved from $23.60 to $24.32 (+3.0%) following better-than-expected results showing reduced losses<\/li>\n<li><strong>July 30, 2025 (Alzheimer&#8217;s Data)<\/strong>: Price jumped 8% after presenting positive biomarker data at AAIC conference<\/li>\n<li><strong>June 9, 2025 (Topline Results)<\/strong>: 12% surge following BROADWAY trial success announcement<\/li>\n<li><strong>May 8, 2025 (Q1 Earnings)<\/strong>: Modest 2% gain on strong cash position reporting<\/li>\n<li><strong>April 2025 (Trial Updates)<\/strong>: Volatile period with prices fluctuating between $14-17 range<\/li>\n<li><strong>March 2025 (Regulatory Prep)<\/strong>: Steady climb as EMA submission preparations advanced<\/li>\n<\/ul>\n<p>The pattern shows that clinical trial results and regulatory milestones create the most dramatic price movements, while earnings reports typically provide more modest but consistent gains.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca Six-Month Performance Deep Dive<\/h2>\n<p>NewAmsterdam&#8217;s stock has been on a remarkable journey over the past six months:<\/p>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Period<\/th>\n<th>Price Range<\/th>\n<th>Key Drivers<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>March 2025<\/strong><\/td>\n<td>$16-18<\/td>\n<td>Early phase trial optimism<\/td>\n<\/tr>\n<tr>\n<td><strong>April 2025<\/strong><\/td>\n<td>$14-17<\/td>\n<td>Market volatility, profit-taking<\/td>\n<\/tr>\n<tr>\n<td><strong>May 2025<\/strong><\/td>\n<td>$18-21<\/td>\n<td>Q1 earnings strength, cash position<\/td>\n<\/tr>\n<tr>\n<td><strong>June 2025<\/strong><\/td>\n<td>$21-24<\/td>\n<td>BROADWAY trial success, publication<\/td>\n<\/tr>\n<tr>\n<td><strong>July 2025<\/strong><\/td>\n<td>$23-25<\/td>\n<td>Alzheimer&#8217;s data surprise, AAIC presentation<\/td>\n<\/tr>\n<tr>\n<td><strong>August 2025<\/strong><\/td>\n<td>$24-26<\/td>\n<td>EMA acceptance, Q2 earnings beat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The stock has shown <strong>+33.70% growth<\/strong> over the past three months and <strong>+6.59%<\/strong> in the last month alone, demonstrating strong momentum heading into the final quarter of 2025.<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<p>Based on current analyst projections and clinical progress, here&#8217;s what you can expect:<\/p>\n<p><strong>2025 Year-End Target<\/strong>: $35-45 range (+44% to +85% from current levels)<\/p>\n<ul>\n<li>Driven by potential EMA approval decision in late 2025<\/li>\n<li>Continued positive clinical data releases<\/li>\n<li>Strong institutional accumulation<\/li>\n<\/ul>\n<p><strong>2026 Projection<\/strong>: $50-65 per share<\/p>\n<ul>\n<li>Assuming successful European market entry<\/li>\n<li>Early revenue generation from obicetrapib sales<\/li>\n<li>Potential US FDA submission progress<\/li>\n<\/ul>\n<p><strong>2028 Outlook<\/strong>: $75-100 per share<\/p>\n<ul>\n<li>Full European commercialization underway<\/li>\n<li>Potential US market approval<\/li>\n<li>Expanded indications beyond cardiovascular<\/li>\n<\/ul>\n<p><strong>2030 Vision<\/strong>: $120-150+ per share<\/p>\n<ul>\n<li>Global market penetration achieved<\/li>\n<li>Multiple revenue streams from different indications<\/li>\n<li>Potential acquisition target for major pharma<\/li>\n<\/ul>\n<p><strong>Current Verdict<\/strong>: STRONG BUY &#8211; The combination of near-term catalysts and long-term growth potential makes NAMS an attractive investment at current levels.<\/p>\n<h2>\u26a0\ufe0f Risk Assessment for Traders<\/h2>\n<h3>Potential Downsides<\/h3>\n<ol>\n<li><strong>Regulatory Risk<\/strong>: EMA or future FDA rejections could crash the stock by 50-70%<\/li>\n<li><strong>Clinical Setbacks<\/strong>: Unexpected safety issues in ongoing trials<\/li>\n<li><strong>Competition<\/strong>: Other CETP inhibitors or new lipid-lowering therapies<\/li>\n<li><strong>Funding Needs<\/strong>: May require additional capital raises diluting shareholder value<\/li>\n<li><strong>Market Volatility<\/strong>: Biotech stocks typically have high beta (2.0+)<\/li>\n<\/ol>\n<h3>Positive Signals for 2025<\/h3>\n<ol>\n<li><strong>EMA Acceptance<\/strong>: Marketing Authorization Application accepted for review (<a href=\"https:\/\/www.newamsterdampharma.com\">Company Announcement<\/a>)<\/li>\n<li><strong>Clinical Success<\/strong>: Multiple Phase 3 trials showing 35-50% LDL-C reduction<\/li>\n<li><strong>Financial Strength<\/strong>: $783.3 million cash position provides runway through 2026<\/li>\n<li><strong>Partnership Value<\/strong>: \u20ac833 million potential milestone payments from Menarini<\/li>\n<li><strong>Market Need<\/strong>: Huge unmet need in statin-resistant patients<\/li>\n<li><strong>Additional Applications<\/strong>: Alzheimer&#8217;s biomarker data opens new markets<\/li>\n<\/ol>\n<h2>\ud83c\udfaf What Should a Beginner Trader Do Today?<\/h2>\n<ol>\n<li><strong>Start Small<\/strong>: Begin with a position size of 1-2% of your portfolio &#8211; biotech is volatile<\/li>\n<li><strong>Dollar-Cost Average<\/strong>: Buy in increments over next 2-3 months around key dates<\/li>\n<li><strong>Set Stop-Losses<\/strong>: Protect downside with 15-20% stop losses given volatility<\/li>\n<li><strong>Watch November 5th<\/strong>: Next earnings could provide better entry if there&#8217;s a pullback<\/li>\n<\/ol>\n<p>Humorous veteran advice: &#8220;Trading biotech stocks is like dating &#8211; exciting potential but prepare for dramatic mood swings. Don&#8217;t fall in love too fast, and always have an exit strategy!&#8221;<\/p>\n<h2>\u2705 Step-by-Step: How to Buy NewAmsterdam Pharma Company N.V. (NAMS) Shares<\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose a Trading Platform<\/td>\n<td>Ensure it offers NASDAQ access and reasonable fees<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete Account Funding<\/td>\n<td>Start with amount you&#8217;re comfortable risking<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Search for &#8220;NAMS&#8221;<\/td>\n<td>Use the ticker symbol, not company name<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Select Order Type<\/td>\n<td>Use limit orders to control entry price<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Review and Execute<\/td>\n<td>Double-check order details before confirming<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Stands Out for New Investors<\/h2>\n<p>For those looking to dip their toes into biotech investing, Pocket Option offers several advantages that make starting your investment journey smoother:<\/p>\n<ul>\n<li><strong>Low Barrier to Entry<\/strong>: With a minimum deposit of just $5, you can begin building your position without significant capital commitment<\/li>\n<li><strong>Rapid Verification<\/strong>: The platform&#8217;s 1-minute KYC process means you can start trading almost immediately after signing up<\/li>\n<li><strong>Flexible Withdrawals<\/strong>: Over 100 withdrawal methods ensure you can access profits conveniently<\/li>\n<li><strong>Educational Resources<\/strong>: The <a href=\"\/blog\">Pocket Option blog<\/a> provides valuable insights for understanding complex biotech investments like NAMS<\/li>\n<\/ul>\n<h2>\ud83c\udfe2 Company Overview: NewAmsterdam Pharma in 2025<\/h2>\n<p>NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company focused on developing obicetrapib, an oral CETP inhibitor for patients with cardiovascular disease who don&#8217;t respond adequately to statin therapy. The company went public in 2022 and has been progressing rapidly through Phase 3 clinical trials.<\/p>\n<p><strong>Current Market Position<\/strong>: <\/p>\n<ul>\n<li>Market capitalization: ~$2.75 billion<\/li>\n<li>Cash position: $783.3 million (as of Q2 2025)<\/li>\n<li>Lead product: Obicetrapib for LDL-C reduction<\/li>\n<li>Partnership: Menarini Group for European commercialization<\/li>\n<\/ul>\n<p><strong>Interesting 2025 Fact<\/strong>: NewAmsterdam&#8217;s research unexpectedly showed that their cardiovascular drug obicetrapib also demonstrated &#8220;statistically significant reductions in key Alzheimer&#8217;s Disease biomarkers&#8221; &#8211; potentially opening a massive new market that nobody saw coming!<\/p>\n"},"faq":[{"question":"Is now a good time to buy NAMS stock?","answer":"Current levels around $24 represent a good entry point before potential EMA approval in late 2025, though be prepared for volatility."},{"question":"What's the biggest risk with investing in NAMS?","answer":"Regulatory rejection would be the most significant risk, potentially cutting the stock price by more than half."},{"question":"How long should I plan to hold NAMS shares?","answer":"This is a 2-5 year investment story - hold through regulatory decisions and initial commercialization."},{"question":"What percentage of my portfolio should be in biotech stocks like NAMS?","answer":"For most investors, keeping biotech exposure below 10-15% of total portfolio is prudent due to volatility."},{"question":"When will the company start generating revenue?","answer":"If approved, revenue could begin in Europe in 2026, with potential US revenue following in 2027-2028."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Is now a good time to buy NAMS stock?","answer":"Current levels around $24 represent a good entry point before potential EMA approval in late 2025, though be prepared for volatility."},{"question":"What's the biggest risk with investing in NAMS?","answer":"Regulatory rejection would be the most significant risk, potentially cutting the stock price by more than half."},{"question":"How long should I plan to hold NAMS shares?","answer":"This is a 2-5 year investment story - hold through regulatory decisions and initial commercialization."},{"question":"What percentage of my portfolio should be in biotech stocks like NAMS?","answer":"For most investors, keeping biotech exposure below 10-15% of total portfolio is prudent due to volatility."},{"question":"When will the company start generating revenue?","answer":"If approved, revenue could begin in Europe in 2026, with potential US revenue following in 2027-2028."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy NewAmsterdam Pharma Company N.V. (NAMS) shares - Investment in NewAmsterdam Pharma Company N.V. (NAMS) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy NewAmsterdam Pharma Company N.V. (NAMS) shares - Investment in NewAmsterdam Pharma Company N.V. (NAMS) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T16:44:33+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy NewAmsterdam Pharma Company N.V. (NAMS) shares &#8211; Investment in NewAmsterdam Pharma Company N.V. (NAMS) stock\",\"datePublished\":\"2025-08-25T16:44:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/\",\"name\":\"How to buy NewAmsterdam Pharma Company N.V. (NAMS) shares - Investment in NewAmsterdam Pharma Company N.V. (NAMS) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"datePublished\":\"2025-08-25T16:44:33+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy NewAmsterdam Pharma Company N.V. (NAMS) shares &#8211; Investment in NewAmsterdam Pharma Company N.V. (NAMS) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy NewAmsterdam Pharma Company N.V. (NAMS) shares - Investment in NewAmsterdam Pharma Company N.V. (NAMS) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/","og_locale":"en_US","og_type":"article","og_title":"How to buy NewAmsterdam Pharma Company N.V. (NAMS) shares - Investment in NewAmsterdam Pharma Company N.V. (NAMS) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T16:44:33+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy NewAmsterdam Pharma Company N.V. (NAMS) shares &#8211; Investment in NewAmsterdam Pharma Company N.V. (NAMS) stock","datePublished":"2025-08-25T16:44:33+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/","name":"How to buy NewAmsterdam Pharma Company N.V. (NAMS) shares - Investment in NewAmsterdam Pharma Company N.V. (NAMS) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","datePublished":"2025-08-25T16:44:33+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy NewAmsterdam Pharma Company N.V. (NAMS) shares &#8211; Investment in NewAmsterdam Pharma Company N.V. (NAMS) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":349312,"slug":"how-to-buy-newamsterdam-pharma-company-nv","post_title":"Comment acheter des actions de NewAmsterdam Pharma Company N.V. (NAMS) - Investir dans les actions de NewAmsterdam Pharma Company N.V. (NAMS)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/"},"it_IT":{"locale":"it_IT","id":349317,"slug":"how-to-buy-newamsterdam-pharma-company-nv","post_title":"Come acquistare azioni di NewAmsterdam Pharma Company N.V. (NAMS) - Investire in azioni di NewAmsterdam Pharma Company N.V. (NAMS)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/"},"pl_PL":{"locale":"pl_PL","id":349318,"slug":"how-to-buy-newamsterdam-pharma-company-nv","post_title":"Jak kupi\u0107 akcje NewAmsterdam Pharma Company N.V. (NAMS) - Inwestycja w akcje NewAmsterdam Pharma Company N.V. (NAMS)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/"},"es_ES":{"locale":"es_ES","id":349315,"slug":"how-to-buy-newamsterdam-pharma-company-nv","post_title":"C\u00f3mo comprar acciones de NewAmsterdam Pharma Company N.V. (NAMS) - Inversi\u00f3n en acciones de NewAmsterdam Pharma Company N.V. (NAMS)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/"},"th_TH":{"locale":"th_TH","id":349314,"slug":"how-to-buy-newamsterdam-pharma-company-nv","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 NewAmsterdam Pharma Company N.V. (NAMS) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 NewAmsterdam Pharma Company N.V. (NAMS)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/"},"tr_TR":{"locale":"tr_TR","id":349321,"slug":"how-to-buy-newamsterdam-pharma-company-nv","post_title":"NewAmsterdam Pharma Company N.V. (NAMS) Hisseleri Nas\u0131l Al\u0131n\u0131r - NewAmsterdam Pharma Company N.V. (NAMS) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/"},"vt_VT":{"locale":"vt_VT","id":349316,"slug":"how-to-buy-newamsterdam-pharma-company-nv","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu NewAmsterdam Pharma Company N.V. (NAMS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu NewAmsterdam Pharma Company N.V. (NAMS)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/"},"pt_AA":{"locale":"pt_AA","id":349313,"slug":"how-to-buy-newamsterdam-pharma-company-nv","post_title":"Como comprar a\u00e7\u00f5es da NewAmsterdam Pharma Company N.V. (NAMS) - Investimento em a\u00e7\u00f5es da NewAmsterdam Pharma Company N.V. (NAMS)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/349211","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=349211"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/349211\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334108"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=349211"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=349211"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=349211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}